Skip to content
Aminoscope
← Research
GLP-1

'Ozempic Babies': GLP-1s, Fertility, and Birth Control

Unexpected pregnancies on GLP-1 drugs come from two real mechanisms: weight loss restoring ovulation, and (for tirzepatide specifically) reduced absorption of oral contraceptives. Here's what the evidence and the labels actually say.

Nadia Feldman7 min read
“Ozempic babies”: two real mechanisms converge on unexpected pregnancyRestored ovulationfrom weight lossReduced absorptionof oral contraceptivesUnexpectedpregnancyTWO REAL MECHANISMS · ONE SURPRISEFertility can rise and the pill can fail at once
Need a closer look?Enlarge illustration

“Ozempic babies” are real and have two causes. Weight loss can restore ovulation, especially in PCOS. And tirzepatide (Mounjaro, Zepbound) can weaken birth-control pills: its label says to use a backup or non-oral method for 4 weeks after starting and after each dose increase. Semaglutide’s label has no such warning but says to stop 2 months before trying to conceive.

“Ozempic babies” started as a social-media curiosity — people on GLP-1 drugs announcing surprise pregnancies, sometimes after years of infertility, sometimes while on birth control. It sounds like a tabloid story, but underneath it are two genuine, separable mechanisms. One makes people more fertile. The other makes one specific drug interfere with the pill. They can act at the same time, which is why the surprises cluster. Here is what the evidence actually supports, kept practical and not alarmist.

Mechanism one: weight loss can restore ovulation

In people with obesity — and especially in polycystic ovary syndrome (PCOS), the most common cause of ovulatory infertility — excess weight and insulin resistance disrupt the hormonal signaling that drives ovulation. Losing weight and improving insulin sensitivity can reverse that disruption and bring ovulation back. A systematic review and network meta-analysis of interventions in reproductive-aged women with overweight or obesity (95 randomized trials, 9,910 women) found that approaches lowering BMI improved ovulation and hormonal profiles. Exercise plus diet plus a weight-lowering drug raised the ovulation rate by a risk ratio of 4.80 (95% CI 1.67 to 13.84) versus control, though more than half the trials carried a high or unclear risk of bias.[1] GLP-1 drugs produce exactly this kind of substantial weight loss, so it is unsurprising that some users conceive when they previously could not.

There is also direct GLP-1 signal in PCOS specifically. In a pilot, open-label randomized study, adding low-dose liraglutide (1.2 mg daily for 12 weeks) to metformin in obese PCOS women who had responded poorly to first-line fertility treatment increased IVF pregnancy rates: 85.7% per embryo transfer versus 28.6% on metformin alone (P = 0.03), across just 28 women, with the two groups losing comparable weight.[2] That is a small, early study, not a license to use these drugs as fertility treatment — but it is consistent with the broader picture: metabolic improvement can translate into improved reproductive odds.[3] Reproductive function and sexual function are separate questions, and they do not move in lockstep: what a GLP-1 does to libido and erections runs through weight rather than any direct action, with an evidenced upside for testosterone and erections in men and a real but under-studied desire signal alongside it.

Mechanism two: tirzepatide can blunt the pill — semaglutide’s label does not

The second mechanism is a true drug interaction, and being precise about which drug matters. Tirzepatide — sold as Mounjaro (diabetes) and Zepbound (weight loss) — delays gastric emptying, and its FDA prescribing information explicitly warns that this can reduce the absorption of orally administered medications, including oral hormonal contraceptives, potentially lowering their effectiveness.[5] The label’s guidance is concrete: people using oral contraceptives should switch to a non-oral method, or add a barrier method, for four weeks after starting tirzepatide and for four weeks after each dose increase. The label notes the delay in stomach emptying is largest after the first dose and fades over time, and that hormonal contraceptives not taken by mouth (such as the patch, ring, implant, hormonal IUD or shot) should not be affected.[5][6] That window (start and every escalation) is exactly when a missed dose of birth control can go unnoticed.

Crucially, semaglutide’s label does not carry the same oral-contraceptive warning. Ozempic, Wegovy and Rybelsus also slow gastric emptying, but the Ozempic label reports that in clinical pharmacology trials semaglutide did not affect the absorption of oral medicines to any clinically relevant degree, and the contraceptive-absorption caution is tirzepatide-specific.[7][5] So a headline like “Ozempic made my birth control fail” is, mechanistically, more accurately a tirzepatide story. For a fuller side-by-side of the two molecules, see our tirzepatide versus semaglutide evidence guide.

Swipe to see all columns

The 'Ozempic babies' pattern has two real drivers: restored fertility from weight loss, and (for tirzepatide specifically) reduced absorption of oral contraceptives.
QuestionWhat the evidence / label supports
Can weight loss restore fertility?Yes — lower BMI can restore ovulation, especially in PCOS
Are GLP-1 drugs fertility treatments?No — fertility gain is a downstream effect, not an indication
Does tirzepatide affect oral birth control?Yes — its FDA label warns of reduced absorption/effectiveness
Does semaglutide's label warn the same?No — that oral-contraceptive warning is tirzepatide-specific
What does the tirzepatide label advise?Add a barrier or switch to non-oral for 4 weeks after start + each dose increase
Safe to use in pregnancy?Not established; semaglutide labels say stop 2 months before a planned pregnancy, Wegovy/Zepbound say stop once pregnant
The 'Ozempic babies' pattern has two real drivers: restored fertility from weight loss, and (for tirzepatide specifically) reduced absorption of oral contraceptives. Ruiz-González 2024 (PMID 38627233); Salamun 2018 (PMID 29703793); Mounjaro, Zepbound, Ozempic and Wegovy prescribing information (DailyMed, 2026)

Pregnancy: stop the drug, mind the washout

Human pregnancy data on GLP-1 drugs are too limited to judge the risk, and animal reproduction studies of both semaglutide and tirzepatide showed fetal harm, so the labels lean hard toward stopping. The weight-loss brands are explicit: weight loss offers no benefit in pregnancy, and Wegovy and Zepbound should be discontinued once a pregnancy is recognized.[6][8] For a planned pregnancy, the semaglutide labels (Ozempic, Wegovy, Rybelsus) say to stop at least 2 months beforehand because of its long washout.[7][8]The tirzepatide labels set no fixed interval; a 2026 clinical review suggests about 8 weeks for both drugs.[4] The diabetes brands (Ozempic, Mounjaro) are a case-by-case call, since uncontrolled diabetes also harms a pregnancy; that is a prescriber decision, not a self-directed one.[5][7] The practical upshot for anyone who could become pregnant on a GLP-1 drug: contraception is not optional, and an unexpected positive test is a prompt to stop the medication and call your prescriber.

The honest bottom line

“Ozempic babies” is not a myth and not magic — it is two real mechanisms stacking up. Weight loss can restore ovulation and raise conception odds, especially in PCOS;[1][2] and tirzepatide specifically can blunt oral birth control during the start-up and dose-escalation windows, which is why its label calls for a backup method.[5] Semaglutide’s label does not carry that contraceptive warning, so keep the two drugs straight. None of these medicines are fertility treatments, and none has established safety in pregnancy: plan the stop with your prescriber (at least 2 months ahead for semaglutide) and let the drug wash out.[4][7] For the weight-loss results that drive the fertility side of this story, see our semaglutide weight-loss trials overview and our results-timeline guide.

Reviewed against primary sources by the Aminoscope desk

Sources

  1. [1] Ruiz-González D, Cavero-Redondo I, Hernández-Martínez A, et al. (2024). Comparative efficacy of exercise, diet and/or pharmacological interventions on BMI, ovulation, and hormonal profile in reproductive-aged women with overweight or obesity: a systematic review and network meta-analysis. Human Reproduction Update. PMID 38627233
  2. [2] Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E. (2018). Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. European Journal of Endocrinology. PMID 29703793
  3. [3] Kettner J, et al. (2026). Glucagon-like Peptide-1 Receptor Agonists and Reproductive Health: Current Evidence and Clinical Implications. Journal of Pharmacy Practice. PMID 40906565
  4. [4] Dilbaz B, et al. (2026). The effects of glucagon-like peptide-1 receptor agonists on fertility, contraception, and pregnancy: clinical perspectives. The European Journal of Contraception & Reproductive Health Care. PMID 41860479
  5. [5] Eli Lilly and Company. (2026). MOUNJARO (tirzepatide) injection: U.S. Prescribing Information, sections 7.2, 8.1 and 8.3 (oral medications, pregnancy, contraception). DailyMed (U.S. National Library of Medicine), label effective August 2026. Source
  6. [6] Eli Lilly and Company. (2026). ZEPBOUND (tirzepatide) injection: U.S. Prescribing Information, sections 7.2, 8.1 and 8.3. DailyMed (U.S. National Library of Medicine), label effective August 2026. Source
  7. [7] Novo Nordisk. (2026). OZEMPIC (semaglutide) injection: U.S. Prescribing Information, sections 7.2, 8.1 and 8.3. DailyMed (U.S. National Library of Medicine), label effective June 2026. Source
  8. [8] Novo Nordisk. (2026). WEGOVY (semaglutide) injection and tablets: U.S. Prescribing Information, sections 8.1 and 8.3. DailyMed (U.S. National Library of Medicine), label effective June 2026. Source

Where to get it

Ozempic alternatives, compared

Cheaper and easier ways to get a GLP-1 than branded Ozempic — compounded semaglutide, tirzepatide, and who offers them.

Compare providers →

Related tool

GLP-1 weight-loss comparison

See semaglutide, tirzepatide, retatrutide and the pipeline ranked by mean trial weight loss — every figure traced to its source.

More in GLP-1